NEW YORK (360Dx) – Roche today announced it received CE mark for the Ventana MMR IHC Panel for aid in diagnosing patients with colorectal cancer.
The panel, which also was launched today, provides clinicians with a group of immunohistochemistry tests for detecting certain proteins associated with mismatch repair, and for differentiating between sporadic colorectal cancer and probable Lynch syndrome. Roche said that about 3 percent of colorectal cancers are associated with Lynch syndrome, which results in a 50 to 80 percent lifetime risk of developing colorectal cancer.
The Ventana MMR IHC Panel includes four assays that target MMR proteins MLH1, PMS2, MSH2, and MSH6, and the Ventana BRAF V600E assay. The panel can be used on the BenchMark GX, XT, and Ultra instruments. It is optimized for use with the OptiView DAB IHC Detection Kit and the OptiView Amplification Kit.